Company intelligence / Profile preview

CHSA

South Florida region, Florida, United Stateschsa.org ↗

Ownership: Private
Development stage: Other

Overview

CHS Pharma has developed a patented multi-drug approach combining G-CSF, DETC-MeSO, and sulindac to address the multifactorial nature of neuronal injury in ischemic stroke and traumatic brain injury. The company also holds IP covering novel treatments for dry AMD using oxidative damage protection. No published human clinical results yet; preclinical data is promising with strong academic backing from Florida Atlantic University researchers.

Therapeutic areas: CardiovascularOphthalmologyNeurology
Modalities: Small moleculeProtein/Growth factorCombination therapy
Industry: Biotech

Partnerships

Collaboration with Florida Atlantic University College of Medicine researchersBoard includes prominent scientists such as Dr. Robert Langer

Beyond the preview

Go deeper on CHSA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHSA.

Explore the full profile